Skip to main content
Interview

Ensartinib Active in Patients With Crizotinib-Resistant, ALK-Positive NSCLC

lzIn an interview with Oncology Learning Network, Li Zhang, MD, Professor of Medical Oncology; Director of the Medical Oncology Department; and Deputy Director of the Lung Cancer Research Center, Sun Yat-sen University Cancer Center, Guangzhou, China, discussed the significance of a clinical trial that established the activity and tolerability of ensartinib therapy for patients with ALK-positive non–small-cell lung cancer (NSCLC) that was unresponsive to crizotinib (Lancet Respir Med. 2020;8[1]:45-53).

What existing data led you and your co-investigators to conduct this research?

ALK gene rearrangements, which encode oncogenic fusion proteins, occur in approximately 5% of patients with NSCLC. Crizotinib is the first approved ALK inhibitor with superior efficacy compared with chemotherapy. However, despite initial response to crizotinib, most patients have disease progression within the first year.

To overcome resistance to crizotinib, several second-generation ALK inhibitors have been developed and entered the clinic, including ceritinib, alectinib, and brigatinib. Nevertheless, acquired resistance also invariably develops against second-generation ALK inhibitors.

Secondary ALK mutations are the most common mechanism of resistance to ALK inhibitors, occurring in 20% to 30% of patients who have disease progression with crizotinib and in approximately 50% of patients whose diseases progress with second-generation ALK inhibitors. Therefore, additional ALK inhibitors are needed to inhibit a broader array of secondary ALK mutations.

Ensartinib is a novel, small-molecule ALK tyrosine kinase inhibitor (TKI). According to enzymatic assays, ensartinib has a potency >10 times greater than crizotinib. More importantly, ensartinib potently inhibited several secondary ALK mutations, including F1174, C1156Y, I1171, S1206R, and T1151.

Additionally, a phase 1/2 study in the United States and a phase 1 study in China both showed promising efficacy and favorable safety profiles of ensartinib in patients with ALK-positive NSCLC. Therefore, my colleagues and I conducted a phase 2 trial to prospectively assess the efficacy and safety of ensartinib and associations between ensartinib efficacy and ALK resistance mutations in patients with crizotinib-refractory, advanced ALK-positive NSCLC.

Please briefly describe your study and its findings. Were any of the outcomes particularly surprising?

This study was a single-arm, open-label, phase 2 trial conducted at 27 centers across China. We enrolled patients who were aged ≥18 years, had stage IIIb or IV ALK-positive NSCLC that had progressed during crizotinib therapy, an Eastern Cooperative Oncology Group performance status of ≤2, had measurable disease, and had received <3 previous treatments.

Patients with central nerve system (CNS) metastases were included if these metastases were asymptomatic. All patients received oral ensartinib 225 mg once daily on a continuous dosing schedule. The primary end point was objective response rate (ORR) assessed by independent review committee.

In total, 160 patients were enrolled in the study and had at least 1 dose of ensartinib. Four patients had inclusion violations and were excluded from the efficacy analysis, which left 156 patients. The systemic ORR and CNS ORR was 52% and 70%, respectively. The median progression-free survival rate was 9.6 months (95% CI, 7.4-11.6), and 91% of 160 patients had at least 1 treatment-related adverse event, which were mostly grade 1 or 2. The most common treatment-related adverse events were rash (56%), increased alanine aminotransferase concentrations (46%), and increased aspartate aminotransferase concentrations (41%).

In this study, we analyzed patients’ circulating tumor DNA at baseline with a 212-gene sequencing panel. We

found that ensartinib had activity against an array of secondary ALK mutations, including C1156Y, F1174, I1171, L1152R/V, and T1151. Surprisingly, 2 of 6 patients harboring G1202R mutations had confirmed partial responses. According to biochemistry assays, ensartinib has only weak activity against G1202R mutations. The underlying mechanisms remain unclear, with a plausible explanation being that the G1202R mutation might have been a minor subclone that was not driving resistance. Further investigation is warranted.

What are the possible real-world applications of these findings in clinical practice?

Based on this study, ensartinib showed confirmed efficacy and unique profiles with respect to activity against ALK mutations. For example, ensartinib is effective among patients harboring certain common ceritinib-resistant mutations (F1174L/V or C1156Y) or alectinib-resistant mutations (I1171T/S).

Ensartinib might be a potential second-line option in this patient population. Of course, lorlatinib has been proven to be a reliable option for this patient population as potent activity has been demonstrated against these mutations. However, whether lorlatinib is an optimal treatment choice for crizotinib-refractory patients is still controversial, considering that the concept of overall oncologic management is emerging and third-generation ALK TKIs are very important salvage therapies for patients resistant to second-generation ALK TKIs.

Therefore, ensartinib will expand the spectrum of activity of currently available ALK TKIs and allow clinicians to personalize ALK-targeted strategies based on the underlying mechanisms of resistance.

Although the efficacy results from the ensartinib trial are generally comparable with alectinib and brigatinib in the post-crizotinib setting, ensartinib appears to have a unique safety profile (high frequency of rash and low frequency of gastrointestinal toxicities). Therefore, ensartinib could be a suitable treatment option for patients who are intolerant to gastrointestinal toxicities of other ALK TKIs.

Additionally, for the current treatment landscape in China, alectinib is only approved for first-line treatment. Brigatinib and lorlatinib have not been marketed in China. Ensartinib has been review by Chinese National Medical Products Administration and will be marketed soon. Therefore, ensartinib will improve the accessibility of new generation ALK TKIs in China.

Do you and your co-investigators intend to expand upon this research?

Yes; in the present study, we didn’t explore the resistant mechanism of ensartinib. However, we have collected the circulating tumor DNA of each patient after disease progression. We will analyze theses samples using next-generation sequencing to reveal the resistant mechanism of ensartinib.

A global, randomized phase 3 trial of ensartinib versus crizotinib in patients with NSCLC who have not previously been treated with ALK TKIs (eXalt3) is ongoing.

Thus, in the near future, ensartinib could be an option not only in the post-crizotinib setting, but also in the first-line setting.